about
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation.Antitumoural activity of a cytotoxic peptide of Lactobacillus casei peptidoglycan and its interaction with mitochondrial-bound hexokinaseBortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.Treatment of refractory chronic GVHD with rituximab: a GITMO study.Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 RExpression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo.Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a GruppAcute promyelocytic leukemia during pregnancy: report of 3 cases.Psychological and sexual disorders in long-term breast cancer survivors.Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.Haemato-oncology and burnout: an Italian surveyEarly measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trialGraft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations.Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation.Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study.Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m(2) plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients.Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.Incidence, risk factors and outcome of pre engraftment Gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey.Steroid treatment of acute graft versus host disease grade I: a randomized trial.Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry.Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas.Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality.Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin.Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study.Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.
P50
Q27690791-BFA05CB1-6DB8-4D23-A1CC-3485221718ACQ28831079-FE7F0912-F1D5-474E-A838-FCBC11F3E9FDQ33371543-C3708FAE-892A-4D8D-8D74-36C3127EC98FQ33375484-50D74853-1C1F-43A8-A4AF-12EA128FAB04Q33401216-10EB081F-D77A-4412-961A-A1EBF74B8F67Q33636086-46F43065-9C24-4EE1-8C13-A5609A7A0707Q33755643-E66C26CC-9CA1-4FC9-B0CE-E7A56A7C9EFAQ35588325-C8B5CF69-2B67-489C-B034-DEE3779BBDEFQ35673677-FD9F1FFA-1593-4201-A47A-C21A6C4D06BDQ35832139-86D4C7AC-2D4A-42BD-95C2-2820B4C8908AQ36416269-6AB06DE2-9666-4A46-9D03-9489311F43C7Q36510099-5D44EEDE-0F07-40C1-B2E0-71A0A911E06DQ36569033-860C3A18-219E-4F90-8A15-77A9D3330B76Q36579055-F0D44051-40C5-44F6-82F5-D944370A200FQ36712054-349D962D-F452-4F2A-8A5F-E67112899DE6Q38324395-92182339-EEDF-40D9-A4CC-F9190FD06318Q38788692-6EC451C1-79A7-44E4-8DD4-794B5647EDC7Q38797546-BC84F78B-5326-4C95-BCD4-0DA54658FE80Q40201079-4994066F-C8F3-436A-AC32-6CC390BA8510Q40211698-16C0018B-2370-4B6B-911E-B6A9E4ADD23AQ40437476-1FCAB2CB-0ABC-428A-88FA-EBA762FB64E8Q40475236-7AE4FC52-7E00-4798-9D66-AC3ECBD87BFEQ40583859-4258166C-964C-49A4-864E-1D5799E4D878Q40843566-480C954A-DE85-4BE8-9261-94789D111566Q41525599-E9128447-B204-4CED-96C7-B63CA1CFC69BQ41987093-0D9F7EE7-B62D-4C8A-BDFC-59FBBECE484AQ41991743-BAAA8E68-D9AC-4975-A04D-7A260A9CF22EQ42223864-5718458F-C213-4D2A-9201-D613B9FAE948Q43607225-2AD1E41F-8A5F-47B5-940E-0DCC8672F728Q43714381-A714352F-9F67-4751-9F88-28F627D6CB41Q43718029-00F51F17-2F36-4D58-A7DB-6400DFCB934CQ44292034-A9796A7B-6F36-40DC-A88A-1E549C08AF16Q44338484-8CCF744B-957C-49DD-B3FC-0E99EEF8D4F4Q45361447-5A246D3B-B2F2-4093-B4DC-D315A76CF7C6Q46123564-EFBD87B0-C2AE-4E37-8CA9-39E2C647DD64Q46921558-0850ABC5-2948-49E6-A9E5-3134DFCB4B1FQ47263508-2DDD6DE3-3F9F-45A4-9734-299357F609CBQ47804783-8CADBDD6-ECA2-4A4C-B18B-A8761F2B6292Q48102813-954E5211-0E34-4E70-82AE-02F5F4328E12Q48251589-2D354EFA-3A08-47C6-AA06-AB5D321E8792
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Milone
@ast
Giuseppe Milone
@en
Giuseppe Milone
@es
Giuseppe Milone
@nl
Giuseppe Milone
@sl
type
label
Giuseppe Milone
@ast
Giuseppe Milone
@en
Giuseppe Milone
@es
Giuseppe Milone
@nl
Giuseppe Milone
@sl
prefLabel
Giuseppe Milone
@ast
Giuseppe Milone
@en
Giuseppe Milone
@es
Giuseppe Milone
@nl
Giuseppe Milone
@sl
P106
P1153
57197792645
P21
P31
P496
0000-0002-7840-4414